SCHEDULE 13G/A: Greenlight Capital Affiliates Disclose 9.9% Stake in Coya Therapeutics
Beneficial Ownership Disclosure
Affiliates of Greenlight Capital, including David Einhorn, have disclosed a 9.9% beneficial ownership stake in Coya Therapeutics, Inc. as of December 31, 2024, according to a recent Schedule 13G/A filing.
Summary
- DME Capital Management, LP, DME Advisors, LP, DME Advisors GP, L.L.C., and David Einhorn (collectively referred to as "Greenlight") are the reporting persons.
- The reporting persons beneficially own an aggregate of 1,651,440 shares of Coya Therapeutics, Inc. common stock.
- This ownership represents 9.9% of Coya Therapeutics, Inc.'s outstanding common stock.
- The calculation of the percentage is based on 16,707,441 shares of Common Stock outstanding as of November 4, 2024, as stated in the company's prospectus dated November 29, 2024.
- The beneficially owned shares include 5,000 shares issuable upon the exercise of warrants.
- The shares are held for private investment funds and managed accounts for which Greenlight acts as investment advisor.
- The filing is an Amendment No. 2 to a Schedule 13G previously filed on December 12, 2023, and amended on February 14, 2024.
- The reporting persons certify that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of the issuer.
Sentiment
Score: 7
Explanation: The disclosure of a significant stake by a prominent institutional investor like Greenlight Capital can be viewed positively by the market, indicating confidence in the company. However, the filing itself is a routine ownership disclosure and does not contain operational or financial performance updates.
Positives
- The disclosure of a significant 9.9% stake by a prominent institutional investor like Greenlight Capital (David Einhorn) can be interpreted as a vote of confidence in Coya Therapeutics, potentially signaling positive long-term prospects to the market.
Future Outlook
This Schedule 13G filing is a disclosure of beneficial ownership and does not contain any forward-looking statements or guidance regarding the company's future performance or operations.
Industry Context
This filing indicates a significant passive investment by a notable institutional fund in Coya Therapeutics, a biotechnology company. Such investments are common across the industry as funds seek to gain exposure to promising companies, particularly in sectors like biotech that may have high growth potential.
Stakeholder Impact
- Shareholders may view the significant stake held by Greenlight Capital as a positive signal of institutional confidence in Coya Therapeutics, potentially influencing investor sentiment and stock price.
Key Dates
| Date | Description |
|---|---|
| 2023-12-12 | Original Schedule 13G filed with the SEC. |
| 2024-02-14 | Date of previous amendment to the Schedule 13G. |
| 2024-11-04 | Date as of which 16,707,441 shares of Common Stock were outstanding, used for percentage calculation. |
| 2024-11-29 | Date of the Company's prospectus stating shares outstanding. |
| 2024-12-31 | Date of event which requires filing of this statement (reporting period end date). |
| 2025-02-14 | Signature date of this Amendment No. 2 to Schedule 13G. |
Keywords
Coya Therapeutics, COYA, Schedule 13G, beneficial ownership, institutional investor, Greenlight Capital, David Einhorn, SEC filing, common stock, investment advisor
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.